S&P 500   4,567.43 (+0.50%)
DOW   35,737.49 (+0.17%)
QQQ   377.71 (+0.96%)
AAPL   148.84 (+0.10%)
MSFT   308.84 (-0.10%)
FB   325.99 (+0.43%)
GOOGL   2,753.68 (+0.09%)
TSLA   997.05 (+9.60%)
AMZN   3,324.30 (-0.34%)
NVDA   232.59 (+2.35%)
BABA   176.05 (-0.93%)
NIO   41.35 (+6.35%)
CGC   13.29 (-0.67%)
GE   105.52 (+1.41%)
AMD   123.31 (+2.91%)
MU   69.00 (+2.21%)
T   25.45 (-0.16%)
F   15.87 (-2.52%)
ACB   7.09 (+0.28%)
DIS   171.69 (+1.34%)
PFE   42.98 (-0.42%)
BA   211.89 (-0.51%)
AMC   37.19 (+1.61%)
S&P 500   4,567.43 (+0.50%)
DOW   35,737.49 (+0.17%)
QQQ   377.71 (+0.96%)
AAPL   148.84 (+0.10%)
MSFT   308.84 (-0.10%)
FB   325.99 (+0.43%)
GOOGL   2,753.68 (+0.09%)
TSLA   997.05 (+9.60%)
AMZN   3,324.30 (-0.34%)
NVDA   232.59 (+2.35%)
BABA   176.05 (-0.93%)
NIO   41.35 (+6.35%)
CGC   13.29 (-0.67%)
GE   105.52 (+1.41%)
AMD   123.31 (+2.91%)
MU   69.00 (+2.21%)
T   25.45 (-0.16%)
F   15.87 (-2.52%)
ACB   7.09 (+0.28%)
DIS   171.69 (+1.34%)
PFE   42.98 (-0.42%)
BA   211.89 (-0.51%)
AMC   37.19 (+1.61%)
S&P 500   4,567.43 (+0.50%)
DOW   35,737.49 (+0.17%)
QQQ   377.71 (+0.96%)
AAPL   148.84 (+0.10%)
MSFT   308.84 (-0.10%)
FB   325.99 (+0.43%)
GOOGL   2,753.68 (+0.09%)
TSLA   997.05 (+9.60%)
AMZN   3,324.30 (-0.34%)
NVDA   232.59 (+2.35%)
BABA   176.05 (-0.93%)
NIO   41.35 (+6.35%)
CGC   13.29 (-0.67%)
GE   105.52 (+1.41%)
AMD   123.31 (+2.91%)
MU   69.00 (+2.21%)
T   25.45 (-0.16%)
F   15.87 (-2.52%)
ACB   7.09 (+0.28%)
DIS   171.69 (+1.34%)
PFE   42.98 (-0.42%)
BA   211.89 (-0.51%)
AMC   37.19 (+1.61%)
S&P 500   4,567.43 (+0.50%)
DOW   35,737.49 (+0.17%)
QQQ   377.71 (+0.96%)
AAPL   148.84 (+0.10%)
MSFT   308.84 (-0.10%)
FB   325.99 (+0.43%)
GOOGL   2,753.68 (+0.09%)
TSLA   997.05 (+9.60%)
AMZN   3,324.30 (-0.34%)
NVDA   232.59 (+2.35%)
BABA   176.05 (-0.93%)
NIO   41.35 (+6.35%)
CGC   13.29 (-0.67%)
GE   105.52 (+1.41%)
AMD   123.31 (+2.91%)
MU   69.00 (+2.21%)
T   25.45 (-0.16%)
F   15.87 (-2.52%)
ACB   7.09 (+0.28%)
DIS   171.69 (+1.34%)
PFE   42.98 (-0.42%)
BA   211.89 (-0.51%)
AMC   37.19 (+1.61%)
NASDAQ:RAIN

Rain Therapeutics News Headlines

$14.02
+0.20 (+1.45 %)
(As of 10/25/2021 12:29 PM ET)
Add
Compare
Today's Range
$13.79
$14.35
50-Day Range
$12.54
$18.40
52-Week Range
$11.57
$23.90
Volume566 shs
Average Volume124,491 shs
Market Capitalization$371.07 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Media Mentions By Week



Rain Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RAIN
News Sentiment

0.00

0.37

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RAIN Articles
This Week

3

1

RAIN Articles
Average Week

Get Rain Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAIN and its competitors with MarketBeat's FREE daily newsletter.

Rain Therapeutics (NASDAQ RAIN) News Headlines Today

SourceHeadline
finance.yahoo.com logoRain Therapeutics Hosting Research and Development (R&D) Day
finance.yahoo.com - October 25 at 9:17 AM
nasdaq.com logoOne Rain Therapeutics Inc. (NASDAQ:RAIN) insider upped their stake by 18% in the previous year
nasdaq.com - October 21 at 3:35 PM
finance.yahoo.com logoRain Therapeutics Inc. (NASDAQ:RAIN) insider upped their holding by 18% earlier this year
finance.yahoo.com - October 21 at 3:35 PM
MarketBeat logoPerceptive Advisors Llc Sells 21,826 Shares of Rain Therapeutics Inc. (NASDAQ:RAIN) Stock
americanbankingnews.com - October 13 at 8:28 PM
MarketBeat logoRain Therapeutics Inc. (NASDAQ:RAIN) Major Shareholder Sells $197,980.08 in Stock
americanbankingnews.com - October 13 at 8:28 PM
MarketBeat logoRain Therapeutics Inc.'s Lock-Up Period To Expire on October 20th (NASDAQ:RAIN)
americanbankingnews.com - October 13 at 1:22 AM
finance.yahoo.com logoRain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 7 at 2:01 PM
finance.yahoo.com logoRain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 4 at 12:41 PM
MarketBeat logoRain Therapeutics Inc. (NASDAQ:RAIN) Receives Average Recommendation of "Buy" from Brokerages
americanbankingnews.com - October 4 at 6:36 AM
benzinga.com logoProthena Announces Executive Appointments
benzinga.com - October 1 at 11:18 PM
finance.yahoo.com logoRain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
finance.yahoo.com - September 22 at 11:08 AM
finance.yahoo.com logoBox, Rain Therapeutics See Activist Action
finance.yahoo.com - September 17 at 11:50 PM
foxnews.com logoMark Levin on Biden's attack on personal freedoms
foxnews.com - September 13 at 11:31 PM
finance.yahoo.com logoRain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 9 at 12:24 PM
finance.yahoo.com logoRain Therapeutics Presents Non-Clinical Data on Milademetan (RAIN-32) in Malignant Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer
finance.yahoo.com - September 8 at 9:33 AM
finance.yahoo.com logoRain Therapeutics to Present at IASLC 2021 World Conference on Lung Cancer and Participate in Panel Discussion at Citi 16th Annual Biopharma Virtual Conference
finance.yahoo.com - September 1 at 9:37 AM
markets.businessinsider.com logoIDEAYA Biosciences to Participate in Investor Conferences in September 2021
markets.businessinsider.com - August 30 at 6:27 AM
finance.yahoo.com logoRain Therapeutics (RAIN) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 11 at 6:55 PM
finance.yahoo.com logoRain Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Progress
finance.yahoo.com - August 10 at 9:17 AM
finance.yahoo.com logoRain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Recent Progress on August 10, 2021
finance.yahoo.com - August 3 at 9:35 AM
finance.yahoo.com logoWe're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate
finance.yahoo.com - July 23 at 12:30 PM
msn.com logoBRIEF-Rain Therapeutics Initiates Phase 3 Mantra Clinical Trial Of Milademetan For De-Differentiated Liposarcoma And Provides Patient Update From Prior Clinical Program
msn.com - July 20 at 12:45 PM
finance.yahoo.com logoRain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program
finance.yahoo.com - July 20 at 12:45 PM
finance.yahoo.com logoRain Therapeutics Inc. (RAIN)
finance.yahoo.com - June 26 at 11:45 PM
finance.yahoo.com logoRain Therapeutics Announces Patient Referral Partnership for the Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32
finance.yahoo.com - June 2 at 8:12 AM
msn.com logoBRIEF-Rain Therapeutics Reports First Quarter 2021 Financial Results And Highlights Recent Progress
msn.com - May 25 at 9:36 AM
finance.yahoo.com logoRain Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Progress
finance.yahoo.com - May 25 at 9:36 AM
finance.yahoo.com logoGoldman Sachs: These 3 Stocks Are Poised to Surge by Over 100%
finance.yahoo.com - May 24 at 1:04 PM
finance.yahoo.com logoRain Therapeutics Appoints Robert Doebele, M.D., Ph.D. as President
finance.yahoo.com - May 20 at 11:35 AM
msn.com logoBRIEF-Bvf Partners LP Says Rain Therapeutics Securities Were "Undervalued"
msn.com - April 28 at 4:41 PM
nasdaq.com logoWednesday 4/28 Insider Buying Report: RAIN, BANC
nasdaq.com - April 28 at 4:41 PM
Get Rain Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAIN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.